Thorac Cardiovasc Surg 2009; 57(1): 35-41
DOI: 10.1055/s-2008-1038985
Original Thoracic

© Georg Thieme Verlag KG Stuttgart · New York

Prospective Study on Perioperative Risks and Functional Results in Bronchial and Bronchovascular Sleeve Resections

J. Schirren1 , S. Bölükbas1 , T. Bergmann1 , A. Fisseler-Eckhoff2 , S. Trainer1 , S. Beqiri1
  • 1Department of Thoracic Surgery, Kerckhoff-Klinik, Bad Nauheim, Germany
  • 2Institute of Pathology and Cytology, Dr.-Horst-Schmidt-Klinik, Wiesbaden, Germany
Weitere Informationen

Publikationsverlauf

received March 20, 2008

Publikationsdatum:
23. Januar 2009 (online)

Abstract

Background: Most reports on sleeve resections are based on a retrospective analysis over a long period of many decades. This prospective study addresses the challenging questions associated with sleeve resection. Methods: In a prospective study, 100 consecutive patients undergoing bronchial or bronchovascular sleeve resection with systematic lymph node dissection were analyzed: operative procedures, extended lymph node dissection, bronchial and vascular complications, functional results, recurrence and survival were recorded. Results: 100 patients (male 78, female 22, age 60.0 ± 11.9) were enrolled in this study. A R0 resection rate of 99 % could be achieved and pneumonectomies avoided using 9 different surgical techniques. The average number of dissected lymph nodes was 30 on the right side and 33 on the left side. Morbidity and mortality were 39 % and 2 %, respectively. The main indication was non-small cell lung cancer (74 %). The local and distant recurrence rates were 1 % and 16 %, respectively. The overall 5-year survival rate was 87 %. Long-term survival differed significantly between N0 and N1 status (p = 0.027) and N0 and N2 status (p = 0.029), but not between N1 and N2 status (p = 0.754). There were no relevant differences in pre- and postoperative perfusion scans and FEV1 at 6 months after surgery. Conclusions: In the hands of experienced surgeons bronchial and bronchovascular sleeve resections are safe operations for high-risk patients. There is no statistical significance between N1 and N2 disease with regard to long-term survival. Systematic lymph node dissection does not lead to increased perioperative risk. Sleeve resections have little effect on pulmonary function. Preoperative FEV1 and lung perfusion can be achieved by 6 months after surgery.

References

  • 1 Angeletti C A, Janni A, Macchiarini P, Ricagna F, Pistelli G. Functional results of bronchial sleeve lobectomy.  Eur J Cardiothorac Surg. 1991;  5 410-413
  • 2 Gaissert H A, Mathisen D J, Moncure A C, Hilgenberg A D, Grillo H C, Wain J C. Survival and function after sleeve lobectomy for lung cancer.  J Thorac Cardiovasc Surg. 1996;  111 948-953
  • 3 Khargi K, Duurkens V A, Versteegh M I, Huysmans H A, Verzijlbergen F F, Quanjer P H, Knaepen P J. Lung function and perfusion after bronchial and pulmonary arterial sleeve resection.  Eur J Cardiothorac Surg. 1996;  10 717-721
  • 4 Cerfolio R J, Bryant A S, Ohja B, Bartolucci A A. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.  J Thorac Cardiovasc Surg. 2005;  130 151-159
  • 5 Schirren J, Richter W, Schneider P, Vogt-Moykopf I. Principles and results of systematic lymph node dissection in surgically treated bronchial carcinoma.  Chirurg. 1996;  67 869-876
  • 6 Schirren J, Muley T, Vogt-Moykopf I. Sleeve lobectomy. Shields TW, LoCicero III J, Ponn RB, eds. General thoracic surgery. 5th ed. Philadelphia, Pennsylvania; Lippincott, Williams & Wilkins 1999: 399-410
  • 7 Travis W D, Brambilla E, Müller-Hermelink H, Harris C, eds. Pathology and genetics of tumors of the lung, pleura, thymus, and heart: WHO classification of tumors. New York; Oxford University Press USA 2004: 59-62
  • 8 Mountain C F. Revisions in the international systems for staging lung cancer.  Chest. 1997;  111 1710-1717
  • 9 Fadel E, Yildizeli B, Chapelier A R, Dicenta I, Mussot S, Dartevelle P G. Sleeve lobectomy for bronchogenic cancers: factors affecting survival.  Ann Thorac Surg. 2002;  74 851-858 858-859
  • 10 Icard P, Regnard J F, Guibert L, Magdeleinat P, Jauffret B, Levasseur P. Survival and prognostic factors in patients undergoing parenchymal saving bronchoplastic operation for primary lung cancer: a series of 110 consecutive cases.  Eur J Cardiothorac Surg. 1999;  15 426-432
  • 11 Okada M, Yamagishi H, Satake S, Matsuoka H, Miyamoto Y, Yoshimura M, Tsubota N. Survival related to lymph node involvement in lung cancer after sleeve lobectomy compared with pneumonectomy.  J Thorac Cardiovasc Surg. 2000;  119 814-819
  • 12 Tronc F, Grégoire J, Rouleau J, Deslauriers J. Long-term results of sleeve lobectomy for lung cancer.  Eur J Cardiothorac Surg. 2000;  17 550-556
  • 13 Terzi A, Lonardoni A, Falezza G, Furlan G, Scanagatta P, Pasini F, Calabro F. Sleeve lobectomy for non-small cell lung cancer and carcinoids: results in 160 cases.  Eur J Cardiothorac Surg. 2002;  21 888-893
  • 14 Kim Y T, Kang C H, Sung S W, Kim J H. Local control of disease related to lymph node involvement in non-small cell lung cancer after sleeve lobectomy compared with pneumonectomy.  Ann Thorac Surg. 2005;  79 1153-1161 1153-1161
  • 15 Mezzetti M, Panigalli T, Giuliani L, Raveglia F, Lo Giudice F, Meda S. Personal experience in lung cancer sleeve lobectomy and sleeve pneumonectomy.  Ann Thorac Surg. 2002;  73 1736-1739
  • 16 Spiguel L, Ferguson K. Sleeve lobectomy versus pneumonectomy for lung cancer in patients with good pulmonary function. Ferguson MK, ed. Difficult decisions in thoracic surgery. London; Springer Verlag 2007: 103-109
  • 17 Ludwig C, Stoelben E, Olschewski M, Hasse J. Comparison of morbidity, 30-day mortality, and long-term survival after pneumonectomy and sleeve lobectomy for non-small cell lung carcinoma.  Ann Thorac Surg. 2005;  79 968-973
  • 18 Martin-Ucar A E, Chaudhuri N, Edwards J G, Waller D A. Can pneumonectomy for non-small cell lung cancer be avoided? An audit of parenchymal sparing lung surgery.  Eur J Cardiothorac Surg. 2002;  21 601-605
  • 19 Mehran R J, Deslauriers J, Piraux M, Beaulieu M, Guimont C, Brisson J. Survival related to nodal status after sleeve resection for lung cancer.  J Thorac Cardiovasc Surg. 1994;  107 576-582 582-583
  • 20 Van Schil P E, Brutel de la Riviere A, Knaepen P J, van Swieten H A, Reher S W, Goosens D J, Vanderschueren R G, van den Bosch J M. Long-term survival after bronchial sleeve resection: univariate and multivariate analyses.  Ann Thorac Surg. 1996;  61 1087-1091
  • 21 Schirren J, Bergmann T, Beqiri S, Bölükbas S, Fisseler-Eckhoff A, Vogt-Moykopf I. Lymphatic spread in resectable lung cancer: can we trust a sentinel lymph node?.  Thorac Cardiov Surg. 2006;  54 372-380
  • 22 Keller S M, Adak S, Wagner H, Johnson D H. Mediastinal lymph node dissection improves survival in patients with stages II and III a non-small cell lung cancer. Eastern Cooperative Oncology Group.  Ann Thorac Surg. 2000;  70 358-365 365-366
  • 23 Rendina E A, Venuta F, De Giacomo T, Ciccone A M, Moretti M, Ruvolo G, Coloni G F. Sleeve resection and prosthetic reconstruction of the pulmonary artery for lung cancer.  Ann Thorac Surg. 1999;  68 995-1001
  • 24 Wood P B, Gilday D, Ilves R, Rea S, Pearson F G. A comparison of gas exchange after simple lobectomy and lobectomy with sleeve resection in dogs.  J Thorac Cardiovasc Surg. 1974;  68 646-653

Dr. MD, PhD Joachim Schirren

Department of Thoracic Surgery
Kerckhoff-Klinik

Beneckestraße 2 – 8

61321 Bad Nauheim

Germany

Telefon: + 49 (0) 6 03 29 96 24 02

Fax: + 49 (0) 6 03 29 96 24 17

eMail: J.Schirren@kerckhoff-klinik.de